Primary biliary cholangitis (PBC) is a chronic progressive autoimmune disorder characterized by small non-purulent ...
Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes– Meeting scheduled ...
Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 ...
Sportschosun on MSN
SGLT2 inhibitors that lower blood sugar, protect heart and kidney...a key treatment for increasing s...
The final thesis of Professor Lim Soo's team of the Department of Endocrine Metabolism at Bundang Seoul National University ...
Lantern Pharma will host a conference call and webcast to discuss third quarter 2025 financial results and business updates on Thursday, November 13, 2025 at 9:00 a.m. Eastern Time.
Q3 2025 Earnings Call Transcript November 4, 2025 Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...
Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associa ...
Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...
The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing ...
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
Immunometabolism have advanced the understanding of dynamic interplay between metabolic pathways and immune responses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback